	US 12,281,337 B2
	GDSL lipase, genetically-engineered bacteria and application thereof
Bin Qi, Suzhou (CN); Manting Qi, Suzhou (CN); Limei Wang, Suzhou (CN); and Yuhua Wang, Suzhou (CN)
Assigned to Suzhou Kemanduo Biotechnology Co., Ltd., Suzhou (CN); and Changshu Institute of Technology, Suzhou (CN)
Filed by Suzhou Kemanduo Biotechnology Co., Ltd., Suzhou (CN); and Changshu Institute of Technology, Suzhou (CN)
Filed on Jun. 27, 2023, as Appl. No. 18/341,792.
Application 18/341,792 is a continuation of application No. 17/279,733, abandoned, previously published as PCT/CN2019/114789, filed on Oct. 31, 2019.
Claims priority of application No. 201910199413.X (CN), filed on Mar. 15, 2019.
Prior Publication US 2024/0011001 A1, Jan. 11, 2024
Int. Cl. C12N 9/20 (2006.01); C12P 7/64 (2022.01); C12P 7/6436 (2022.01)

CPC C12N 9/20 (2013.01) [C12P 7/6436 (2013.01)]

9 Claims

1. A method for production of vitamin A palmitate, comprising:

(1) inoculating an engineered bacterium containing a recombinant vector comprising the GDSL lipase nucleotide sequence of SEQ ID NO:1 into an LB medium for seed culture;

(2) transferring the seed solution to a fermentation medium for fermentation culture, and then adding an inducer to induce expression of the GDSL lipase nucleotide sequence of SEQ ID NO:1;

(3) centrifuging the fermentation broth to obtain a supernate, and obtaining GDSL lipase powder through precipitation by ammonium sulfate and lyophilization; and

(4) adding the GDSL lipase powder to an organic phase system containing vitamin A and palmitic acid to produce vitamin A palmitate.